Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China
← catalyst calendarNCT06332014 · readout in 157 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
102actual
Sites
16
Country
China
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-06 | actual | When the study began enrolling |
| Primary completion | 2027-01-23 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-01-23 | estimated | The whole study's end, after follow-up |
| First posted | 2024-03-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Osteoporosis
Intervention
- Drug: Prolia — also filed as Denosumab
Primary outcome
what the primary-completion date above is the date OFPercent change from baseline in bone mineral density (BMD) of lumbar spine at month 12
measured Baseline and Month 12
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed